Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

1 Oct 2022

Abstract excerpt

Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36244343
DOI: 10.1016/j.celrep.2022.111554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesPMID 36244343Read ↗

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read ↗

A Long Interval Between Priming and Boosting SARS-CoV-2 mRNA Vaccine Doses Enhances B Cell Responses With Limited Impact on T Cell ImmunitySemantic proximity Read ↗

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read ↗

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read ↗

Immunogenicity and clinical outcomes of booster mRNA vaccine BNT162b2 in primary antibody deficienciesSemantic proximity Read ↗

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity Read ↗

Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity Read ↗

Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccineSemantic proximity Read ↗

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read ↗

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic reviewSemantic proximity Read ↗

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesSemantic proximity Read ↗

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.